Testosterone Replacement Therapy in Hypogonadal Men and Myocardial Infarction Risk: Systematic Review & Meta-Analysis

Jun Hee Lee 1, Pratha H. Shah 1, Davuluri Uma 1, Dhairea J. Salvi 1, Rizwan Rabhani 1, Pousette Hamid 5

1. Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA  2. Nephrology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA  3. Neurology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA

Corresponding author: Jun Hee Lee, drmdlee1992@gmail.com

Abstract
Testosterone replacement therapy (TRT) has become increasingly popular over the years and there has been an increasing debate on whether testosterone replacement should be offered to older men due to its association with cardiovascular events. In this study, we evaluated the risk of myocardial infarction (MI) associated with TRT in hypogonadal men through a meta-analysis. We carried out the analysis by following the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines and conducted a literature search utilizing the following databases: Google Scholar, PubMed, Science Direct, Cochrane Library trials, and ClinicalTrials.gov. The search strategy resulted in a total of 782 articles, after applying our inclusion and exclusion criteria. Six observational studies and two randomized controlled trials (RCTs) were included for the analysis. A total of 55,806 hypogonadal men with baseline testosterone levels <300ng/mL were included in the analysis. The intervention group received testosterone in various routes including transdermal patches, gels, mouth patches, testosterone injections, and depot. The incidence of MI was taken to be the primary measure outcomes. The pooled data from eight studies showed MI incidence in 249 out of 11,720 (2.1%) in the TRT group and 1420 out of 55,086 (4.3%) in the control group. The pooled OD showed no statistically significant association of TRT and MI compared to the control group (OR = 0.76, 95% CI 0.56-1.31; p = 0.48). The model revealed high heterogeneity with I² = 79%. With sensitivity analysis and excluding two studies out of the eight, the pooled data was able to achieve low heterogeneity with I² = 0%. The newly pooled data from six studies showed MI incidence in 226 out of 10,137 (2.2%) in the TRT group and 969 out of 56,304 (2.7%) in the control group. The pooled OD shows no statistical significance in the association between TRT treatment and MI compared to the control group. (OR = 0.87, 95% CI 0.75-1.01; P = 0.08). It appears that TRT does not increase the risk of MI as compared to the non-intervention group. Further RCTs with greater population size are needed that could produce more solid results, allowing more definitive conclusions to be made on this topic.

Introduction And Background
Hypogonadism in men is a growing burden for the population around the world. It is estimated that the overall prevalence rate of hypogonadism in men for the general population in the United States (US) is between 5.8-20.4%, Chile 28.1%, Germany 5.4-5%, Finland 19.8%, Malaysia 6-16.1%, Taiwan 12.0%, and Hong Kong 9.5% [1].

Testosterone is the primary sex hormone in males and it is produced mainly by the Leydig cells of the testes in men under the stimulation by luteinizing hormone. In a normal male, approximately 7mg of testosterone is produced daily and the testis produces 95% of circulating testosterone [2]. Homeostasis of testosterone levels is achieved by the hypothalamic-pituitary-gonadotropin axis. Primary hypogonadism is caused by disruption at the level of the testis whilst secondary form is due to disruption at the level of the hypothalamus and pituitary. A decline in testosterone level in older men is associated with impaired mobility, lower muscle strength, and a decrease in muscle mass [3,4]. Testosterone replacement therapy (TRT) has been shown to have benefits on sexual function, mood and depressive symptoms, physical performance, and an increase in lean body mass [5-7]. In the US, approximately 51% of men experience sexual dysfunction [8].

With the combination of the aging population with hypogonadism and the shown benefits of testosterone, TRT has become increasingly popular over the years. In the US alone, annual testosterone spending has increased around four-folds between 2007 and 2016, expenditure had risen from $108 million to $402 million [9]. The use of testosterone is not without side effects. Some of the more established possible adverse effects relating to TRT include polycythemia, fluid retentions, exacerbation of sleep apnea, gynecomastia, and liver toxicity [10-12].

American Urological Association (AUA) suggests that the diagnosis of testosterone deficiency should be achieved by a total testosterone level lower than 500ng/dL measured on two separate occasions in patients who present with symptoms of hypogonadism [13]. Physicians encountering men with androgen deficiency
who presents with suggestive symptoms, sexual dysfunction, decreased muscle strength, and poor quality of life may be interested in using testosterone for treatment. However, an unestablished clear relationship between cardiovascular consequences of TRT may be a limiting factor when weighing the possible risks and benefits of the treatment. AUA guideline recommends that cardiovascular disease risk assessment should be done before the start of the testosterone therapy for hypogonadal men. The guideline, however, also states that there is no definitive evidence between the relationship between testosterone therapy and the risk of cardiovascular events and, hence, there is no clear guideline associated with it [13].

It has been shown that testosterone can induce coronary artery relaxation, a direct androgen effect on the vessels independent of conversion to estrogen [14]. Mathur et al. demonstrated long-term testosterone therapy significantly delayed time to exercise–induced myocardial infarction (MI) [15], whilst other studies have shown testosterone therapy and its possible association with increased thrombotic events [16].

The cardiovascular safety of TRT has been debated over the years with mixed results in the literature. In this meta-analysis, we are hoping to answer this question by finding the possible relationship between TRT used in hypogonadal men and the risk of MI. We want to establish evidence-based effects (benefits or risks) associated with testosterone therapy that can aid clinicians in discussing informed discussion about testosterone therapy and the risk of MI with their patients. In doing so, we systematically reviewed the best available evidence about the relationship between testosterone use and the incidences of MI in men.

**Review**

**Methodology**

This meta-analysis was carried out in the accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [17].

**Databases**

Systemized search of the articles was done in PubMed, Google Scholar, Science direct and Cochrane Library trials, and ClinicalTrials.gov. Only articles published in the English language were considered. The last search was done on April 17, 2021. The following search terms were used in combination: "Testosterone replacement", "Testosterone", "Testosterone therapy" "hypogonadism", "Myocardial infarction", "Cardiovascular event", "MACE", and "adverse event". On PubMed, MeSH (Medical Subject Headings) search strategy was used: Myocardial infarction OR Coronary artery disease OR Heart attack AND Testosterone replacement therapy OR Testosterone therapy OR Testosterone AND Hypogonadal men OR hypogonadism AND ("Myocardial Infarction/epidemiology" (Majr) OR "Myocardial Infarction/statistics and numerical data" (Majr) OR "Myocardial Infarction/therapy" (Majr)) OR ("Myocardial Infarction/epidemiology" (Majr) OR "Myocardial Infarction/classification" (Majr) OR "Myocardial Infarction/therapy" (Majr)) OR ("Myocardial Infarction/classification" (Majr) OR "Myocardial Infarction/statistics and numerical data" (Majr) OR "Myocardial Infarction/therapy" (Majr)) AND ("Testosterone/adverse effects" (Majr) OR "Testosterone/deficiency" (Majr) OR "Testosterone/therapeutic use" (Majr) OR "Testosterone/therapy" (Majr) OR "Testosterone/deficiency" (Mesh:NoExp) OR "Testosterone/therapeutic use" (Mesh:NoExp) OR "Testosterone/therapy" (Mesh:NoExp) AND ("Hypogonadism/classification" (Majr) OR "Hypogonadism/drug therapy" (Majr) OR "Hypogonadism/mortality" (Majr) OR "Hypogonadism/therapy" (Majr) OR ("Hypogonadism/classification" (Mesh:NoExp) OR "Hypogonadism/drug therapy" (Mesh:NoExp) OR "Hypogonadism/mortality" (Mesh:NoExp) OR "Hypogonadism/therapy" (Mesh:NoExp)). The search was filtered to include only studies published after 2010.

**Eligibility Criteria and study selection**

Two investigators (IL, PS) screened each article’s title and abstract to determine eligibility independently first. Then the studies included by both reviewers were compared and disagreements were resolved by consensus. When the consensus could not be reached between the two investigators, the third independent investigator (UD), who did not participate in the original screening, decided the eligibility. The following inclusion criteria were utilized to screen the results: 1) Full-text articles available, 2) Studies published in the English language, 3) Observational and randomized controlled trials (RCT) that explore the relationship between TRT and MI, 4) Studies conducted on human males who have lower testosterone levels irrespective of age, ethnicity, or study location, 5) Included studies even if MI was not the principal endpoint, and 6) Studies including hypogonadal men with <300ng/dL testosterone at baseline.

The exclusion criteria included were: 1) Editorials, posters, and animal studies, 2) Irrelevant studies, 3) Studies conducted only including specific populations with certain comorbidities e.g diabetes, post-MI, heart failure, or any other, 4) Studies that did not observe MI incidence was excluded, and 5) Studies using androgens other than testosterone. Only studies meeting the above criteria were evaluated for eligibility in the final review.

**Data Extraction**

Two independent investigators (IL, PS) performed data extraction from the selected studies. All of the following variables were investigated using a standardized recording tool: study design, number of study participants, baseline characteristics of participants including comorbidities and testosterone level, mode of
treatment and treatment dose, the mean follow-up in each group of participants, study outcomes, and whether the study was funded by a pharmaceutical company.

**Quality Assessment Tools**

Two investigators evaluated the risk of bias, using the Newcastle-Ottawa questionnaire for the observational studies (Table 1) and Cochrane risk-of-bias tool (Table 2) for clinical trials. We only included studies that had scores six and above in the Newcastle-Ottawa questionnaire for the observational studies and RCT, we only included studies that were judged as "low-risk" of bias in each of the domains. Disagreement was resolved by consensus.

### TABLE 1: Quality assessment of observational studies using the Newcastle-Ottawa questionnaire

| Study               | Selection | Comparability | Outcome | Overall (max 9) |
|---------------------|-----------|---------------|---------|-----------------|
| Traish et al. [18]  | ★★★       | ★             | ★       | 6, Good         |
| Vigen et al. [19]   | ★★★       | ★             | ★       | 6, Good         |
| Cheetham et al. [20]| ★★★★★     | ★             | ★       | 7, Good         |
| Ramasamy et al. [21]| ★★★       | ★             | ★       | 6, Good         |
| Maggi et al. [22]   | ★★★★      | ★             | ★★★     | 8, Good         |
| Pantalone et al. [23]| ★★★★     | ★             | ★       | 7, Good         |

### TABLE 2: Quality assessment of RCT using the Cochrane risk-of-bias tool

| RCT                | Selection bias | Reporting bias | Performance bias | Detection bias | Attrition bias |
|--------------------|----------------|----------------|------------------|----------------|----------------|
| Basaria et al. [24]| Low Risk       | Low Risk       | Low Risk         | Low Risk       | Low Risk       |
| Basaria et al. [25]| Low Risk       | Low Risk       | Low Risk         | Low Risk       | Low Risk       |

**Data analysis**

We performed the final statistical analysis using the Review Manager (RevMan) version 5.4 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen). For dichotomous results, we calculated the risk and OR and 95% CI using the random-effects model and the Mantel-Haenszel method. Statistical significance was described when the two-sided p-value was <0.05.

The heterogeneity was calculated using $I^2$ statistics. As explained in the *Cochrane Handbook for Systematic Reviews* [26], $I^2 > 50\%$ was considered to be substantial heterogeneity. We carried out sensitivity analysis for significant heterogeneity.

**Results**

**Literature search and study selection**

Our search strategy yielded the following: Pubmed using MeSH keys words filtering to include studies from 2010-2021, full text available, article type to include clinical trial, and RCT yielded 294, ScienceDirect yielded 106 after filtering research articles only and studies after 2010, Clinicaltrials.gov yielded 35, Cochrane library of clinical trials yielded 49, Google Scholar 300 of the first sorted by relevance was added out of the total 5960. The search strategy was used totaling 782 in all. After applying inclusion and exclusion criteria, and duplication removal, 16 full-text articles were found to be potentially eligible. Of these, eight articles were identified as suitable for our research question. This is represented in Figure 1.
Baseline Characteristics of Included Studies

The characteristics of the included studies are shown in Table 3. Out of the eight studies included in our study, two were RCT, two were prospective cohort and the remaining four out of the eight studies were retrospective cohort studies.

| Study | Study Design | TRT group | Control group | TRT Mean age | Control Mean age | Total sample size (n) | Number of patients taking TRT (n) | Number of patients in control group (n) | Mean baseline total testosterone levels (Treatment) | Mean baseline total testosterone levels (Control) | Testosterone dose/mode | Co-morbidities in the TRT group | Co-morbidities in the control group | Mean follow-up period | Number of MI in treatment group | Number of MI in control group | Conclusion regarding CV events and TRT |
|-------|--------------|-----------|---------------|-------------|-----------------|----------------------|-------------------------------|----------------------------------------|-----------------------------------------------|----------------------------------|-----------------|--------------------------------|--------------------------------|-------------------|-----------------------------|-----------------------------|----------------------------------|
| Traish et al. [18] | Observational, Prospective, Cohort Study | 57.4 | 64.8 | 624 | 386 | 9.8mmol/L | 9.8mmol/L | Parenteral T undecanoate 1000mg/12 weeks | DM1 6.7% | DM1 1.4% | 7 years | 0 | 31 | Lower Risk of CV events in TRT group |
| | | 66.9 | 68.3 | 306 | 151 | 8.6mmol/L | 8.6mmol/L | 75mg of Testosterone gel – prematurely stopped at 6 months due to increased adverse reactions | DM1 | DM1 | 16% | 6 months | 0 | 2 | Increases risk of CV events in TRT group |
| Basaria et al. [24] | RCT | 66.9 | 68.3 | 306 | 151 | 8.6mmol/L | 8.6mmol/L | 75mg of Testosterone gel – prematurely stopped at 6 months due to increased adverse reactions | DM1 | DM1 | 16% | 6 months | 0 | 2 | Increases risk of CV events in TRT group |
| Study                | Design          | Patient Details | Follow-up | Testosterone Treatment | Hypertension (%) | Diabetes (%) | Obesity (%) | Hyperlipidemia (%) | CVD (%) | Other Conditions                  |
|---------------------|-----------------|----------------|-----------|------------------------|------------------|--------------|-------------|---------------------|---------|-----------------------------------|
| Vigen et al. [19]   | Retrospective   | 63.8; 60.6; 67.4; 72.0 | 7-98; 986; 1220 | Gel/patch/Injection Dose N/A | 63.8 | 60.6 | 8704 | 1223 | 7486 | 5.06mmol/L | 5.96mmol/L | 27.5 months | 23 | 620 |
| Cheetham et al. [20] | Retrospective   | 58.4; 59.6 | 6365; 6988; 33327 | all patients = 6.6mmol/L | 53.2% | 53.2% | 44.5% | 57.5% | DM | Hypertension: 58.6% | 60.4% | 53.2% | 53.2% | 44.5% | 57.5% | 6.2 median years in the TRT treatment group and 3.3 median years in the control group | 354 | 962 |
| Ramasamy et al. [21] | Retrospective   | 74; 73 | 217; 153 | 64 | all patients = 3.0mmol/L | 58.6% | 53.2% | DM | Hypertension: 58.6% | 60.4% | 53.2% | 53.2% | 44.5% | 57.5% | 6.2 median years in the TRT treatment group and 3.3 median years in the control group | 354 | 962 |
| Haggii et al. [22]  | Prospective     | 56.9; 59.7 | 806; 750 | 349 | 8.3mmol/L | 9.6mmol/L | N/A | Hypertension: 46.5% | 44.2% | 4.2 median years in the TRT treatment group and 3.2 median years in the control group | 3.8 median years in the TRT treatment group and 3.4 median years in the control group | 1 | 0 |
| Basirian et al. [25] | RCT             | 74; 74 | 208; 166 | 193 | 250ng/dL | 230ng/dL | N/A | Testosterone Gel: 50ng/dL intramuscularly c1 for 6 months, then 2 weeks after dose adjusted to <17nmol/L, vs 34.7nmol/L | Hypertension: 85% | 84% | 65% | 60% | 65% | 60% | No difference in the risk of CV event between the c and 1 group | 11 | 2 |
| Pantalone et al. [23] | Retrospective   | 55 (median years) | 275; 165; 210 | 178mmol/L | 173mmol/L | NeA | Hypertension: 67.2% | 67.8% | 45.6% | 46.1% | 45.6% | 46.1% | No difference in the risk of CV event between the c and 1 group | 4 | 3 |

DM: Diabetes, CHF: Congestive Heart Failure, OSA: Obstructive Sleep Apnea, COPD: Chronic Obstructive Pulmonary Disease, CV: Cardiovascular, CVD: Cerebrovascular Disease, Peripheral: Peripheral Vascular Disease, Previous MI: Previous Myocardial Infarction, Total Vascular Disease: Total Vascular Disease, Total Hypertension: Total Hypertension, Total Obesity: Total Obesity.
The pooled data from eight studies showed MI incidence in 249 out of 11,720 (2.1%) in the TRT group and 1420 out of 33,086 (4.3%) in the control group. Figure 2 reveals pooled estimate which showed no statistically significant association of TRT and MI compared to the control group. (OR = 0.76, 95% CI 0.36-1.31; p=0.48). The model revealed high heterogeneity with $I^2$ = 79%. With sensitivity analysis, by excluding Vigen et al. and Traish et al., the pooled data was able to achieve low heterogeneity with $I^2$ = 0%. The newly pooled data from six studies showed MI incidence in 226 out of 10,137 (2.2%) in the TRT group and 969 out of 36,304 (2.7%) in the control group. Figure 3 reveals no statistical significance in the association between TRT treatment and MI compared to the control group. (OR =0.87, 95% CI 0.75-1.01; P =0.08). The funnel plot was used to assess the publication bias. A visual assessment of Figure 5 showed slight asymmetry, suggestive of possible publication bias, thus we used a random effect model to analyze the selected studies.

**TABLE 3: Baseline characteristics of included studies**

T = testosterone, DM = diabetes mellitus, MI = myocardial infarction, CAD = coronary artery disease, RCT = randomized controlled trial, N/A = not available, CHF = congestive heart failure, OSA = obstructive sleep apnea, COPD = chronic obstructive pulmonary disease, CVD = cardiovascular disease, CV = cardiovascular

| Study or Subgroup   | Testosterone | Control | Weight | N/A Risk | 95% CI       | Year    |
|---------------------|--------------|---------|--------|----------|--------------|---------|
| Basnak 2010         | 3            | 100     | 0      | 100      | 0.32(0.21, 0.49) | 2010    |
| Basnak 2015         | 3            | 105     | 2      | 151      | 1.47(0.64, 2.92) | 2015    |
| Ramashevo 2016      | 1            | 153     | 0      | 64       | 1.27(0.66, 2.46) | 2016    |
| Rago 2016           | 1            | 750     | 2      | 249      | 0.94(0.80, 1.10) | 2016    |
| Chdoherm 2017       | 20H          | 909     | 298    | 362      | 0.89(0.73, 1.09) | 2017    |
| Traish 2017         | 4            | 291     | 3      | 296      | 0.91(0.80, 1.04) | 2017    |
| Fortisio 2019       | 4            | 165     | 3      | 210      | 1.71(1.28, 2.27) | 2019    |
| Total (95% CI)      | 11720        | 48868   | 100    | 105      | 0.69(0.56, 0.86) |         |

**FIGURE 2: Forest plot comparing odds ratio of myocardial infarction for testosterone therapy vs control**

The Cochran-Mantel-Haenszel method and the random-effects model were used to calculate the pooled odds ratio.

**FIGURE 3: Forest plot comparing odds ratio myocardial rates for testosterone replacement therapy vs. control**

After removing two studies by performing sensitivity analysis, the pooled data show low heterogeneity, $I^2$ = 0%.
Discussion

A meta-analysis by Maggi, et. al. [27], which included 70 studies, has indicated that patients with cardiovascular disease have significantly lower testosterone levels and higher 17-beta estradiol levels. The higher incidence of overall mortality and cardiovascular-related mortality in patients were found in lower baseline testosterone levels in longitudinal studies. Also, TRT was linked to a substantial increase in treadmill test length as well as the time to 1mm ST-segment depression. Other results from retrospective epidemiological studies support this conclusion given by the meta-analysis [28,29].

However, simply replacing testosterone with TRT in patients with a low blood level of testosterone does not necessarily guarantee that the risk of cardiovascular disease and/or overall mortality will be lowered. It is unclear whether low testosterone and cardiovascular risk have a true cause-and-effect relationship. On the other hand, low testosterone may be just an indicator of overall health.

The Testosterone in Older Men (TOM) trial [25] was stopped at six months due to increased adverse events, more specifically cardiovascular-related events, in the treatment with the testosterone gel group. However, there are some controversies regarding the results of this study. The TOM trial had a small number of participants (209), and its study population consisting of only older men with limitations in mobility and a high prevalence of comorbidities. Also, the study was not designed to study cardiovascular events as a primary outcome. However, with these growing concerns, in 2015, FDA drug safety communication issued a warning against using testosterone treatments to treat low testosterone due to aging. It had mandated a labeling change to inform of an elevated risk of MI and stroke with its use [30].

In our meta-analysis study, no statistically significant difference was found in the overall incidence of MI in hypogonadal men receiving testosterone therapy compared to hypogonadal men not taking any testosterone therapy. This finding is coherent with the 2014 statement from the European Medicine Agency (EMA), which stated that there is no clear evidence that testosterone medications raise cardiovascular risk in hypogonadal men [31].

The link between testosterone therapy and heart disease is complicated. Testosterone medication can raise or decrease the risk of adverse cardiovascular events through a variety of physiological routes. Testosterone therapy can cause edema, hypertension, and heart failure by increasing salt and water retention [32,33]. Testosterone can upregulate the expression of thromboxane A2 receptors, resulting in platelet aggregation and an increase in thrombotic events such as MI [34]. Left ventricular hypertrophy, systolic and diastolic dysfunction from testosterone are also possible [35].

In contrast, there are other pathways in which testosterone may potentially reduce the risk of cardiovascular disease. Testosterone therapy may improve cardiovascular health by lowering fat mass, lipid profile, and insulin sensitivity. Furthermore, testosterone may have anti-inflammatory properties, which had been shown to reduce the thickness of carotid intima-media [36]. As there are various ways in which testosterone can influence the cardiovascular system, conducting more extensive studies on the biological mechanism of testosterone is imperative.
In the intention to treat an observational cohort study by Wallis et al. [37], which included 40,289 men over the age of 66, concluded that long-term TRT (median 35 months) was linked to lower mortality and cardiovascular events. In contrast, short-term TRT (median two months) increased the risk of mortality and cardiovascular events. However, this study lacked data on the baseline testosterone level in their studied subjects as well as the reasoning behind the testosterone therapy on their patients.

Traish et al. [18] also concluded with similar results. This study followed 360 hypogonadal men treated with testosterone for eight years and compared against 296 men with hypogonadism without treatment for the same follow-up period. This study also showed that mortality related to cardiovascular disease was significantly lower in the testosterone group. Moreover, the anthropometric parameters and other cardiovascular risk factors such as blood glucose levels were also compared in this study. There was a reduction in waist circumference and BMI in the testosterone treatment group compared to the untreated group, as well as a reduction in blood glucose shown through measurement of HbA1c levels in the testosterone treatment group. However, as this study included men with Klinefelter syndrome and other primary hypogonadism patients who had to receive testosterone therapy, its treatment group was considerably younger than the control group and potential selection bias.

Normalization of Testosterone Levels and the Risk of Myocardial Infarction

Sharma et al. [38] made an outcome distinction in the TRT group, differentiating the outcome on whether the patient was normalized to normal testosterone level or had failed to achieve normal testosterone level without TRT. In this retrospective study, patients were divided into these three groups: no treatment, TRT with normalization of serum testosterone, TRT without normalization of serum testosterone. In comparison between the TRT treatment group who had failed to achieve normal testosterone level and the no treatment group, there was no statistical difference in MI, all-cause mortality, and stroke. On the other hand, patients with normalization of testosterone after TRT had a lower risk of MI, all-cause mortality, and stroke, compared to no treatment group or TRT without normalization of testosterone group. In comparison with normalized treated with untreated men for MI risk, the adjusted hazard ratio was 0.76 with a CI of 0.63-0.95. Comparing MI risk for normalized TRT group compared with those who did not have normalized testosterone levels after TRT, the adjusted hazard ratio was 0.82 with CI 0.71-0.95.

These findings suggest that normalization of testosterone with TRT may be the key factor in the association between TRT and the risk of MI. As this study only includes men without prior MI and stroke, more studies on other populations are needed to establish a more clear association with the normalization of testosterone with TRT in hypogonadal men and the lowered risk of MI and overall mortality.

Limitations

There are certain limitations to this study, which are mostly attributed to the limitations of the studies that were included. First, we only included only eight studies that met our inclusion criteria. The result produced with all studies produced high heterogeneity. However, with sensitivity analysis and including only six out of the eight studies, the heterogeneity of the analyses was found to be low (6%). We have included retrospective observational studies and non-randomized assignments in these studies that may have offered certain bias risks. For example, testosterone therapy itself was not free for most patients, there could be some selection bias present in selected studies as some patients may not have decided to receive testosterone therapy due to its cost. However, we do not believe that this would have a significant impact on our findings. Our meta-analysis was based on pooled data. We did not have access to certain crucial information about the individual participants who suffered MI. The eight studies selected were not designed or powered to address the risk of MI with testosterone therapy in hypogonadal men specifically. To our knowledge there are no studies that investigated this topic specifically, meeting our study selection criteria to this date. However, most of the selected studies were investigating cardiovascular events as a primary outcome, and we believe that our study results should be considered hypothesis-generating. We do not believe that our results are definitive and that it provides sufficient evidence for the safety of testosterone usage in hypogonadal men with the risk of MI. However, the findings from this study may help doctors discussing potential benefits and risks in initiating TRT in hypogonadal men.

Conclusions

In conclusion, this meta-analysis found no statistically significant difference between the risk of MI and testosterone therapy in hypogonadal men compared to non-treated hypogonadal men. As there are no long-term prospective placebo-controlled trials to investigate the MI risks and benefits of testosterone therapy in men with hypogonadism, we do not believe that this finding provides definitive evidence for cardiovascular safety in the use of testosterone replacement TRT in hypogonadal men. However, findings from this paper may aid doctors counseling hypogonadal men about the benefits and risks of TRT before initiating the treatment. Moreover, our study warrants the need for more future RCTs measuring more specific parameters such as the duration of testosterone therapy, the methods of testosterone therapy, and the normalization of testosterone level in hypogonadal men with greater population size, which could produce more solid results, allowing more definitive conclusions to be made on this topic.

Additional Information
Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Zarotsky V, Huang MY, Carman W, Morgentaller A, Singhal PK, Coffin D, Jones TH: Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Androlology. 2014, 2:819-54. 10.1111/andr.2014.2.819-54

2. O'Donnell L, Stanton P, de Kretser DM: Endocrinology of the male reproductive system and spermatogenesis [Endotext: Internet]. Feingold KR, Anawalt B, Boyce A, et al. (ed): MDText.com, Inc, South Dartmouth, MA; 2017.

3. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ: Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev. 1999, 107:123-36. 10.1016/s0047-6374(98)00150-4

4. Schaap LA, Pluim SJM, Smit JH, van Schoor NM, Visser M, Groen LJ, Lips P: The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women. Clin Endocrinol (Oxf). 2005, 63:152-60. 10.1111/j.1365-2265.2005.02315.x

5. Emmelot-Vonck MH, Verhaar HJ, Nakhiour Pour HR, et al.: Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008, 299:39-52. 10.1001/jama.2007.51

6. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremmer WJ, Tenover JL: Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005, 90:1502-10. 10.1210/jc.2004-1957

7. Snyder PJ, Bhasin S, Cunningham GR, et al.: Effects of testosterone treatment in older men. N Engl J Med. 2016, 374:611-24. 10.1056/NEJMoa1506119

8. Laumann EO, Paik A, Rosen RC: Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999, 281:537-44. 10.1001/jama.281.6.537

9. Morden NE, Wolsztyn S, Brooks CG, Schwartz LM: Trends in testosterone prescribing for age-related hypogonadism in men with and without heart disease. JAMA Intern Med. 2019, 179:446-8. 10.1001/jamainternmed.2018.6505

10. Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I, Rudman D: Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc. 1995, 43:899-901. 10.1111/j.1532-5415.1995.tb05334.x

11. Schneider BK, Pickett CK, Zwillich CW, et al.: Influence of testosterone on breathing during sleep. J Appl Physiol (1985). 1986, 61:618-23. 10.1152/jappl.1986.61.2.618

12. Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM: Liver damage from long-term methyltestosterone. Lancet. 1977, 310:261-63. 10.1016/s0140-6736(77)96949-7

13. Mulhall JP, Tracht LW, Braunig RB, et al.: Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018, 200:423-32. 10.1016/j.juro.2018.03.115

14. Deenadayalu V, Puttabayappat A, Liu AT, Stallone JN, White RE: Testosterone-induced relaxation of coronary arteries: activation of BKCa channels via the cGMP-dependent protein kinase. Am J Physiol Heart Circ Physiol. 2012, 302:H115-23. 10.1152/ajpheart.00466.2011

15. Mathur A, Malkin C, Sared B, Mathusamy R, Jones TH, Chanter K: Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol. 2009, 161:443-9. 10.1530/EJE-09-0092

16. Glueck CJ, Richardson-Royer C, Schultz R, Burger T, Bowe D, Padda J, Wang P: Testosterone therapy, thrombophilia-hypofibrinolysis, and hospitalization for deep venous thrombosis-pulmonary embolus: an exploratory, hypothesis-generating study. Clin Appl Thromb Hemost. 2014, 20:244-9. 10.1177/1076029613499819

17. Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136/bmj.n71

18. Trath SH, Haider A, Haider KS, Doros G, Saad F: Long-term therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (control) groups. J Cardiovasc Pharmacol Ther. 2017, 22:414-33. 10.1177/1074248417691136

19. Vigen R, O'Donnell CI, Baron AE, et al.: Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013, 310:1829-36. 10.1001/jama.2013.28036

20. Cheetham TC, An J, Jacobsen SJ, Niu F, Sidney S, Quesenberry CP, VanDenEeden SK: Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency. JAMA Intern Med. 2017, 177:491-9. 10.1001/jamainternmed.2016.9546

21. Ramasastry R, Scowell J, Mederos M, Ren R, Jain L, Lipshultz L: Association between testosterone supplementation therapy and thrombotic events in elderly men. Urology. 2015, 86:283-5. 10.1016/j.urology.2015.03.049

22. Maggi M, Wu FC, Jones TH, et al.: Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME). Int J Clin Pract. 2016, 70:845-52. 10.1111/ijcp.12857

23. Pantalone KM, George I, Ji X, et al.: Testosterone replacement therapy and the risk of adverse cardiovascular outcomes and mortality. Basic Clin Androl. 2019, 29:5. 10.1186/s12610-019-0085-7

24. Basaria S, Harman SM, Travison TG, et al.: Effects of testosterone administration for 3 years on subclinical atherosclerotic progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015, 314:570-81. 10.1001/jama.2015.8881

25. Basaria S, Covello AD, Travison TG, et al.: Adverse events associated with testosterone administration. N Engl J Med. 2010, 363:109-22. 10.1056/NEJMoa1000485

2021 Lee et al. Cureus 13(8): e17475. DOI 10.7759/cureus.17475 9 of 10
26. Higgins JP, Altman DG, Gøtzsche PC, et al.: The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ. 2011, 343:d5928. 10.1136/bmj.d5928
27. Corona G, Rastrelli G, Monami M, et al.: Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011, 165:687-701. 10.1530/EJE-11-0447
28. Laughlin GA, Barrett-Connor E, Bergstrom J: Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008, 93:68-75. 10.1210/jc.2007-1792
29. Tivesten A, Vandenput L, Labrie F, Karlsson MK, Ljunggren O, Melinsson D, Ohrsson C: Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab. 2009, 94:2482-8. 10.1210/jc.2008-2650
30. FDA drug safety communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. (2015). Accessed: July 8, 2021: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-cautions-about-using-testost...
31. No consistent evidence of an increased risk of heart problems with testosterone medicines . (2014). Accessed: July 8, 2021: https://www.ema.europa.eu/en/news/no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines.
32. Johannsson G, Gibney J, Wolthers T, Leung KC, Ho KK: Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. J Clin Endocrinol Metab. 2005, 90:3989-94. 10.1210/jc.2005-0553
33. Quan A, Chakravarty S, Chen JK, et al.: Androgens augment proximal tubule transport. Am J Physiol Renal Physiol. 2004, 287:F452-9. 10.1152/ajprenal.00188.2003
34. Ajayi AA, Mathur R, Halushka PV: Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation, 1995, 91:2742-7. 10.1161/01.cir.91.11.2742
35. D’Andrea A, Caso P, Salerno G, et al.: Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis. Br J Sports Med. 2007, 41:149-33. 10.1136/bjsm.2006.030173
36. Heusleder AE, Saad F, Bunck MC, Gooren L: Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009, 30:726-33. 10.2164/jandrol.108.007005
37. Wallis CJ, Lo K, Lee Y, et al.: Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes Endocrinol. 2016, 4:498-506. 10.1016/S2213-8587(16)00112-1
38. Sharma R, Oni OA, Gupta K, et al.: Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015, 36:2706-15. 10.1093/eurheartj/ehv346